Veracyte | VCYT - Current Liabilities


Veracyte reported $62.74M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
Agilent USD 2.27B 35M Mar/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Bruker USD 1.2B 150.4M Jun/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Illumina USD 1.58B 12M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Laboratory Of America USD 2.12B 516.4M Jun/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Siemens EUR 49.52B 168M Mar/2026
Sonic Healthcare AUD 2.23B 92.84M Dec/2024
Thermo Fisher Scientific USD 15.07B 448M Jun/2026
Veracyte USD 62.74M 6.62M Jun/2026
Waters USD 2.27B 1.03B Mar/2026